The frequencies of individuals with CKD Stages 3-5 (eGFR < 60 mL/min/1.73 m 2 ) increased over the three decades in both sexes. Despite the widespread use of antihypertensive agents, the proportions of individuals with CKD who reached blood pressure of <130/80 mmHg were only 27.0% in men and 47.5% in women. The frequency of metabolic disorders including diabetes, hypercholesterolaemia and obesity increased over the three decades in both sexes. Conclusions. The prevalence of CKD increased significantly in men, but not in women over the last three decades in a general Japanese population. Our findings support the requirement for a comprehensive treatment for hypertension and metabolic disorders to reduce the burden of CKD.
Introduction
Chronic kidney disease (CKD), most commonly defined by a reduction in kidney function or the presence of proteinuria [1, 2] , is increasingly recognized as a leading public health issue. The number of patients with endstage kidney disease has been expanding rapidly and is predicted to exceed 2 million worldwide by the year 2010 [3] . Furthermore, it has been established that CKD is a risk factor not only for progressive kidney failure, but also for cardiovascular morbidity and mortality [4] [5] [6] .
Several cross-sectional studies have demonstrated that CKD affects 10-15% of the adult population in developed Western countries [7] [8] [9] . Recent epidemiological studies have suggested that CKD may be more prevalent in Asian countries than in developed Western countries [10, 11] . Furthermore, it has been reported that the number of patients undergoing dialysis in Asian countries such as Malaysia and Japan has been increasing [12, 13] . It is likely that the prevalence of CKD would increase over time as a consequence of the accumulation of risk factors such as hypertension, glucose intolerance, obesity and hypercholesterolaemia, probably owing to the westernization of the lifestyle in these Asian countries. However, there are limited data assessing secular trends in the prevalence of CKD in general Asian communities to date. A better understanding of the past and current prevalence of CKD and its potential risk factors may provide useful information for the development of management strategies for CKD.
The Hisayama Study is a community-based cohort study that has been underway since 1961, with a goal of estimating the effects of the remarkable lifestyle changes on the burden of cardiovascular diseases in Japan [14] [15] [16] [17] . The aim of the present study is to assess trends in the prevalence of CKD and its risk factors over the last three decades and to examine their relationships.
Subjects and methods

Study population
The town of Hisayama is a suburban community adjacent to Fukuoka City, a metropolitan area on Kyushu Island in southern Japan. The population of the town has been stable for 50 years and was approximately 8000 in 2008. The age and occupational distributions of the Hisayama population are almost identical to those of Japan as a whole. Full commu-nity surveys of the residents have been repeated from the initiation of the study to date. The study design and characteristics of the subject population have been described in detail elsewhere [14] [15] [16] [17] [18] . Briefly, four study cohorts composed of Hisayama residents aged ≥40 years were established in 1961, 1974, 1988 and 2002 . For this study, we used data from the cross-sectional surveys conducted at baseline in the latter three cohorts, which included available data on serum creatinine and proteinuria. The full community surveys were conducted as follows. In 1974, we invited all 2629 residents in that age group in the town registry to participate in the survey by the assistance of the town office, and of those, 2135 (participation rate, 81.2%) consented to participate in the health examination. After excluding 17 subjects for whom blood samples were unavailable, 2118 subjects (911 men, 1207 women) were enrolled in this study. In the same manner, 2741 subjects from 2742 participants (participation rate, 80.9%) in 1988 and 3297 subjects from 3298 participants (participation rate, 77.6%) in 2002 were enrolled in the study. A total of 3059 (38%) subjects participated in two or more of the three surveys.
Definition of CKD
Details of the measurement of risk factors in each survey were described previously [15, 16, 18, 19] . Freshly voided urine samples were tested by the dipstick method in all surveys. Proteinuria was defined as 1+ or more. Serum creatinine was measured by the non-compensated Jaffé method in 1974 and 1988 and the enzymatic method in 2002. Serum samples were assayed using a Technicon autoanalyser (Technicon Instruments, Tarrytown, NY) in 1974, a TBA-80S autoanalyser (Toshiba Inc., Tokyo, Japan) in 1988 and an AU-800 autoanalyser (Olympus Corporation, Tokyo, Japan) in 2002. The difference between the serum creatinine levels by the Jaffé method and those by the enzymatic method was calibrated by using 98 serum samples standardized by CRC Corporation (Fukuoka, Japan). The range of creatinine levels in the samples was 0.5 to 15.2 mg/dl by the Jaffé method. The conversion equation was estimated by using a simple linear regression model. The correlation coefficient of this equation was 0.996. The Jaffé method value was converted to an enzymatic method value by using the following equation: 
Risk factors
In each survey, blood pressures were measured three times in a sitting position after at least 5 min of rest, and the mean of the three measurements was used for the analysis. Hypertension was defined as a mean systolic blood pressure ≥140 mmHg or a mean diastolic blood pressure ≥90 mmHg or a current use of antihypertensive agents. Subjects with hypertension were classified as treated or untreated based on whether or not they were currently using antihypertensive agents. . Body height and weight were measured in light clothing without shoes, and the body mass index (in kilogrammes per square metre) was calculated. Obesity was defined as a body mass index ≥25 kg/m 2 . Metabolic syndrome was defined by using criteria recommended in a joint interim statement of five major scientific organizations [21] . Information on medical history, medical treatment, alcohol intake and smoking habits was obtained through a standard questionnaire by trained interviewers. Alcohol intake and smoking habits were classified as either current habitual use or not.
Statistical analysis
The prevalences of CKD and each risk factor were adjusted for the age distribution of the world standard population in 1998 by using the direct method. The age-adjusted mean values of risk factors were calculated using the analysis of covariance method with age included as a continuous variable. Trends in the prevalence or mean values of each factor across survey years were assessed by fitting the logistic or linear regression model with evenly spaced numeric codes for the survey year, respectively. The age-adjusted relative risk (RR) and its 95% confidence interval (95% CI) for CKD were estimated by using Poisson regression analysis [22] . The SAS software package, release 9.2 (SAS Institute, Cary, NC), was used to perform all statistical analyses. A two-tailed value of P < 0.05 was considered statistically significant.
Results
We compared the age-adjusted prevalence and mean values of risk factors among the three surveys by sex, as shown in Table 1 . The prevalence of hypertension was constant in men, but decreased in women from 1974 to 2002. The prevalence of treated hypertension increased over time, whereas the prevalence of untreated hypertension decreased in both sexes. Consequently, mean blood pressure levels decreased over the last three decades. The frequencies of diabetes, hypercholesterolaemia, obesity, metabolic syndrome and alcohol intake increased with time, whereas the frequency of smoking habits decreased in both sexes. The prevalence of diabetes, especially untreated diabetes, increased with time in both sexes. Figure 1 presents the age-adjusted prevalence of CKD in the three surveys by sex. The age-adjusted prevalence of CKD increased significantly with time in men (13.8% in 1974, 15.9% in 1988 and 22.1% in 2002; P for trend < 0.001), but not in women (14.3%, 12.6% and 15.3%, respectively; P for trend = 0.9). The prevalence of CKD Stages 3-5 increased 3-fold over time in men (4.8%, 9.4% and 15.7%; P for trend < 0.001) and doubled in women (5.8%, 9.9% and 11.7%; P for trend < 0.001). Conversely, the prevalence of CKD Stages 1-2 decreased to two-thirds in men (9.0%, 6.5% and 6.4%; P for trend = 0.02) and by half in women (8.5%, 2.7% and 3.4%; P for trend < 0.001). Similar trends in the prevalence of CKD across the three surveys were also observed in middle-aged and elderly populations in either sex (Figure 2 ). There was a comparable relationship for the prevalence of 2558 M. Nagata et al. Survey year * P for trend < 0.01 * P for trend < 0.05, ** P for trend < 0.01, *** P for trend 0.001 Next, we estimated the frequencies of well-controlled blood pressure in men and women with CKD in each of the three surveys (Figure 3 ). Among subjects with CKD, the proportion with blood pressure levels of <140/90 mmHg increased from 46.6% in 1974 to 51.1% in 2002 for men and from 47.0% to 66.6% for women, in parallel with the increment in the proportion of subjects taking antihypertensive agents. The frequency of blood pressure of <130/80 mmHg was <30% in men with CKD in all three surveys, whereas it increased from 24.9% in 1974 to 47.5% in 2002 in women. Among CKD subjects taking antihypertensive agents in 2002, 36.3% of men and 26.3% of women had a blood pressure level <140/90 mmHg, and only 11.1% and 12.8%, respectively, had a blood pressure level <130/ 80 mmHg. Table 2 shows the age-adjusted prevalence and RR of CKD by the status of hypertension treatment among the three surveys by sex. For men, the RR of presence of CKD increased with time in subjects with untreated hypertension (P for trend = 0.001), but not in subjects with treated hypertension (P for trend = 0.48). For women, there was no evidence of significant differences in the prevalence of CKD over time in any of the hypertension treatment statuses.
Finally, we assessed the relationship between metabolic syndrome and the risk of CKD in 1988 and 2002. Metabolic syndrome was associated with an increased risk of prevalent CKD in either sex (Figure 4) . The strength of the relationship did not change over time for men (P for heterogeneity = 0.99), whereas it was attenuated significantly in 2002 compared with 1988 for women (P for heterogeneity = 0.01).
Discussion
In the present study, we demonstrated that the prevalence of CKD increased significantly in men, but not in women from the 1970s to the 2000s in a general Japanese population, whereas CKD Stages 3-5 increased progressively with time in both sexes. Importantly, more than half of Prevalence of CKD in Japan 2561 individuals with CKD did not reach the optimal target levels of blood pressure recommended by the current guidelines [23, 24] , despite an increment in the proportion of subjects taking antihypertensive agents over the last three decades. Furthermore, our findings implied that the recent increment in the number of subjects with metabolic disorders is linked to the increasing prevalence of CKD. These analyses, therefore, would seem to highlight the importance of the comprehensive management of metabolic disorders in addition to the strict control of blood pressure in order to reduce the burden of CKD in the general Japanese population. The prevalences of CKD have been reported for several countries. The National Health and Nutrition Examination Surveys reported that the age-adjusted prevalence of CKD Stages 1-4 among subjects aged 20 years or older in the United States increased from 10.0% in 1988-1994 to 13.1% in 1999-2004 [8] . In Nord-Trondelag, Norway, the prevalence of CKD Stages 3-5 was 4.4% [9] . CKD may be more prevalent in Asian countries than in developed Western countries. A cross-sectional study conducted in 574 024 Japanese subjects over 20 years old demonstrated that the prevalence of CKD Stages 3-5 was 10.6 % in Japan [11] . Data from the screenings in Okinawa, Japan showed that the unadjusted prevalence of CKD Stages 3-5 among subjects aged 20 years or older increased between 1993 (10.4%) and 2003 (12.2%) in men, but decreased in women (19.5% in 1993, 17.4% in 2003), although the average serum creatinine levels increased in all age categories during this period in either sex [25] . An increasing trend in the prevalence of CKD in men was thus observed both in our study and Okinawa's study. The discrepancy observed in women between the two studies may have arisen from a self-selection bias caused by the low participation rate (<20%) in Okinawa's study, with subjects having an underlying disease (e.g. advanced kidney disease) being less likely to participate in the examination. Importantly, the prevalences of CKD in these studies were estimated on the basis of different eGFR equations, the direct comparison of which might be inappropriate. A nationwide examination will be needed to estimate the burden of CKD in Japan more reliably.
In the present study, the prevalence of metabolic disorders, such as diabetes, hypercholesterolaemia and obesity, was found to have increased dramatically over the last three decades, probably due to the westernization of lifestyle in Japan [26] . In the 2002 survey, diabetes was significantly associated with the likelihood of CKD for both sexes. Diabetes is an especially serious problem in the prevention strategy for CKD because it has been the leading cause of end-stage renal disease since 1998 in Japan [13] . Likewise, hypercholesterolaemia and obesity have been shown to be independent risk factors for CKD [27, 28] . Our findings showed a jump in the prevalence of metabolic disorder from 1974 to 1988 ahead of the increment in the prevalence in CKD, possibly suggesting a causal association of metabolic disorder with the risk of CKD. In this study, furthermore, metabolic syndrome, which is defined as the accumulation of three or more risk factors such as elevated blood pressure, glucose intolerance, central obesity and dyslipidemia, was associated with an increased risk of CKD. Our previous longitudinal study has demonstrated that individuals with metabolic syndrome have 2.1-fold greater risk than those without it [29] . It has also been reported that clusters of multiple metabolic disorders tended to cause CKD in the several epidemiological studies [30, 31] . Therefore, it is reasonable to suppose that the increasing prevalence of metabolic disorders has contributed to the increasing trend in CKD, especially CKD Stages 3-5, in our subjects.
Hypertension is well-established as a powerful risk factor for not only cardiovascular disease, but also CKD [32] . In this study, blood pressure levels significantly declined in both sexes over the last three decades, probably because of the widespread use of antihypertensive medication. Nevertheless, about 70% of men with CKD and 50% of women with CKD did not reach the optimal blood pressure levels of <130/80 mmHg even in the latest survey. Several clinical trials have demonstrated that blood pressure lowering was beneficial for the prevention of progressive kidney disease [33, 34] and cardiovascular disease in individuals with CKD [35] [36] [37] [38] . A recent meta-analysis of Japanese cohort studies also revealed that lower blood pressure level is linearly associated with a lower risk of cardiovascular disease and death in subjects with CKD [39] . These findings, therefore, suggest that blood pressure should be controlled more strictly in individuals with CKD, using the recommendations in the current guidelines [23, 24] .
Our study showed that the prevalence of CKD Stages 1-2 decreased over the last three decades in both sexes. Importantly, the frequency of women with CKD Stages 1-2 was halved over time, and therefore, the overall prevalence of CKD did not change. In the 2002 survey, blood pressure was well-controlled in women, compared with men (Table 1) . It has been established that blood pressure-lowering therapy, particularly the use of reninangiotensin system inhibitors, reduces the risk of the development of proteinuria and subsequent kidney dysfunction [40] [41] [42] [43] [44] [45] . Furthermore, the relationship between metabolic syndrome and the likelihood of CKD for women tended to be attenuated from the 1988 survey to the 2002 survey, possibly due to early interventions, including lifestyle modification or medications against metabolic disorder. Thus, our findings imply that optimal management of blood pressure and metabolic disorder may reduce the prevalence of CKD in women in the next decade.
Several limitations of our study should be noted. First, it is well-known that eGFR values calculated using the MDRD study equation with a single measure of serum creatinine are not fully accurate. In addition, measurement of serum creatinine was not repeated after an interval of at least 3 months. Additionally, the values of serum creatinine were not calibrated using the values from the Cleveland Clinic, although they were calibrated across the three surveys. These matters may have caused some degree of misclassification of eGFR levels. Nevertheless, these limitations may have had little effect on our conclusions because the extent of misclassification of eGFR levels would be similar across the surveys. Second, the method for measuring serum cholesterol could not be calibrated across the surveys in this study. However, we believe that our findings with regard to the trend in the propor-2562 M. Nagata et al.
tion of hypercholesterolaemia over time are likely to be real because the proportion of obesity showed a similar pattern. Third, a 75-g oral glucose tolerance test was not performed in 1974. Thus, the prevalence of diabetes in 1974 was likely to be underestimated because the glucose tolerance test is a more sensitive method to diagnose diabetes. Fourth, the blood pressure levels were estimated with office blood pressure measurement, but not with home blood pressure monitoring, likely attenuating the accuracy of the information about blood pressure control. Fifth, we were unable to obtain information regarding the cause of CKD or the type of antihypertensive drugs, including renin-angiotensin system inhibitors. This information would have enabled a deeper understanding of our results. Finally, this is a cross-sectional study, and thus, the data are of limited use in inferring causality between risk factors and CKD.
Conclusion
In conclusion, the prevalence of CKD increased significantly in men, but not in women from the 1970s to the 2000s in a general Japanese population. Despite the popularization of antihypertensive medication, blood pressure was not sufficiently controlled over time to meet the optimal level recommended by the current guidelines for patients with CKD. Additionally, the increasing prevalence of metabolic disorders would be expected to play a role in the increasing trend in CKD. Our findings support the requirement for a comprehensive treatment for hypertension and metabolic disorders in order to reduce the burden of CKD.
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